Patents by Inventor Tanya MacNeil

Tanya MacNeil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy for the treatment of obesity
    Publication number: 20060270650
    Abstract: The present invention relates to compositions comprising calcium and/or xanthan gum and an anti-obesity agent, useful for the treatment and prevention of diabetes, obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.
    Type: Application
    Filed: May 8, 2006
    Publication date: November 30, 2006
    Inventors: Tanya MacNeil, Douglas MacNeil
  • Strain of streptomyces avermitilis capable of glycosylating avermectin compounds at the 13- and 14A positions
    Patent number: 5312753
    Abstract: Avermectin compounds are glycosylated at the 4',13- Or 14a-positions by adding the avermectin compounds to the fermentation medium of a novel strain of Streptomyces avermitilis. The 13-hydroxy and 14a-hydroxy methyl groups of the avermectin compound are glycosylated with a glycosyl moiety, specifically an oleandrose group. The new strain offers the added advantage of not producing any C5-O-methylation products. The compounds are potent anthelmintic and antiparasite agents, and compositions for such uses are also disclosed.
    Type: Grant
    Filed: March 23, 1992
    Date of Patent: May 17, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Douglas J. MacNeil, Tanya MacNeil
  • Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
    Patent number: 5252474
    Abstract: There are disclosed plasmids containing DNA isolated from Streptomyces avermitilis, the microorganism which is used to prepare avermectin compounds, identified as pAT1, pVE650 pVE855, pVE859, pVE1446, pVE923, and pVE924 which contain the genetic information for the biosynthesis of the avermectins. Methods for the isolation of such plasmid and for the manipulation of the plasmids to alter the formation of the avermectin compound are also disclosed.
    Type: Grant
    Filed: March 14, 1990
    Date of Patent: October 12, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Keith M. Gewain, Douglas J. MacNeil, Tanya MacNeil, Philip S. Paress, Carolyn L. Ruby, Stanley L. Streicher
  • RDNA cloning vector pVE1, deletion and hybrid mutants and recombinant derivatives thereof products and processes
    Patent number: 4703009
    Abstract: Novel plasmid pVE1, deletion mutants thereof, recombinant derivatives thereof, which is the same as the genome or nucleic acid of such plasmids and derivatives of such genome, which are useful as recombinant DNA cloning vectors into host organisms, such as bacteria, for example, Streptomyces avermitilis; portions of such plasmid genome are additionally useful as adjuncts in recombinant DNA cloning procedures, for examples: 1. to permit the maintenance of cloned DNA in the host, either in an integrated state or as an autonomous element; 2. to serve as promoters for increasing expression of endogenous or foreign genes wherein said promoters are ligated to such genes or otherwise serve as promoters; and 3.
    Type: Grant
    Filed: December 4, 1985
    Date of Patent: October 27, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Tanya MacNeil, Patrice H. Gibbons